Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-09-28
2000-11-14
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
51425501, 514575, A61K 31192, A61K 315375, A61P 3500
Patent
active
061470740
ABSTRACT:
A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.
REFERENCES:
Parker et al,, The Development of 27023A. Poster P73 at the Seventh International Conference of the Inflammation Research Association, Sep. 25-26, 1994X.
J. Morphy et al., "Matrix Metalloproteinases Inhibitors: Current Status," Current Medicinal Chemistry, 2, 743-762 (1995).
W. Hagmann et al., "Inhibition of Matrix Metalloproteinases," Annual Reports in Medicinal Chemistry, 31, 231-240, (1996).
Summers et al., "Matrix Metalloproteinase Inhibitors and Cancer," Annual Reports in Medicinal Chemistry, 33, 131-140 (1998).
Rizzi James P.
Robinson Ralph P.
Butterfield Garth
Ginsburg Paul H.
Pfizer Inc
Ramsuer Robert W.
Richardson Peter C.
LandOfFree
Arylsulfonylamino hydroxamic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylsulfonylamino hydroxamic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonylamino hydroxamic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065638